JSC

Market Access

Unlocking oncology access: What the OECD findings mean for m...

New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks